lentiviral vlp stock  (Worthington Biochemical)


Bioz Verified Symbol Worthington Biochemical is a verified supplier
Bioz Manufacturer Symbol Worthington Biochemical manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
    Name:
    Deoxyribonuclease I
    Description:
    Chromatographically purified A lyophilized powder with glycine as a stabilizer
    Catalog Number:
    ls002004
    Price:
    33
    Size:
    5 mg
    Source:
    Bovine Pancreas
    Cas Number:
    9003.98.9
    		Buy from Supplier

    Structured Review

    Worthington Biochemical lentiviral vlp stock
    Nullbasic does not inhibit the production of <t>lentiviral</t> VLPs. (a) Schematic diagrams of the three <t>VLP</t> expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Chromatographically purified A lyophilized powder with glycine as a stabilizer
    https://www.bioz.com/result/lentiviral vlp stock/product/Worthington Biochemical
    Average 85 stars, based on 1155 article reviews
    Price from $9.99 to $1999.99
    lentiviral vlp stock - by Bioz Stars, 2020-10
    85/100 stars

    Related Products / Commonly Used Together

    nacl
    mgcl2
    edta
    kcl
    rna
    triton x-100
    dtt
    sds
    protease inhibitor cocktail
    pbs
    total rna
    hepes
    egta
    pmsf
    cdna

    Images

    1) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Figure Legend Snippet: Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Techniques Used: Expressing, Plasmid Preparation

    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Figure Legend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Techniques Used: Purification, Activity Assay

    2) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced
    Figure Legend Snippet: Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Techniques Used: Infection, Produced

    HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was
    Figure Legend Snippet: HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Techniques Used: Expressing, Infection

    HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were
    Figure Legend Snippet: HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Techniques Used: Expressing, Infection

    3) Product Images from "A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells"

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    Journal: Human Gene Therapy

    doi: 10.1089/hum.2012.176

    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Figure Legend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Techniques Used: Purification, Activity Assay

    Related Articles

    In Vitro:

    Article Title: Extracellular traps are associated with human and mouse neutrophil and macrophage mediated killing of larval Strongyloides stercoralis
    Article Snippet: .. Treatment with DNase I eliminated the presence of released DNA, but did not block killing of the larvae by mouse neutrophils and macrophages in vitro. .. This observation suggests that in contrast to human neutrophils and macrophages, mouse cells do not require ET formation in vitro to kill the worms.

    Blocking Assay:

    Article Title: Extracellular traps are associated with human and mouse neutrophil and macrophage mediated killing of larval Strongyloides stercoralis
    Article Snippet: .. Treatment with DNase I eliminated the presence of released DNA, but did not block killing of the larvae by mouse neutrophils and macrophages in vitro. .. This observation suggests that in contrast to human neutrophils and macrophages, mouse cells do not require ET formation in vitro to kill the worms.

    Produced:

    Article Title: Novel High-Throughput Deoxyribonuclease 1 Assay
    Article Snippet: .. The percentage of DNase I activity was calculated using Equation 1: DNase\u00a0I\u00a0activity (%) =\u00a0 (mean\u00a0velocity\u00a0of\u00a0a\u00a0compound/mean\u00a0velocity\u00a0of\u00a0DMSO)\u00a0\u00d7\u00a0100 (1) In similar assays, recombinant murine EndoG (produced in-house) was used at a concentration of 0.14 μM in 0.1 mM MgCl2 , 10 mM Tris-HCl, pH 7.4; and DNase II (Worthington, Lakewood, NJ) (3.32 nM) was tested in 100 mM sodium citrate buffer, pH 5.0. .. For evaluation of the quality of the assay, Z’ values were calculated using Equation 2: Z\u2019 =\u00a01\u00a0\u2212\u00a0(3SDC +\u00a03SDB )/(MC \u00a0\u2212\u00a0MB ) (2) where M = mean value; SD = standard deviation; C = control; and B = background.

    Concentration Assay:

    Article Title: Interactions of NBU1 IntN1 and Orf2x Proteins with Attachment Site DNA
    Article Snippet: .. DNase I (Worthington) diluted in DNase I dilution buffer (2.5 mM MgCl2 , 0.5 mM CaCl2 , 10 mM Tris-HCl, pH 7.6, 0.1 mg/ml BSA) to a final concentration of 0.0625 μg/ml was incubated with reaction mixtures for 1 min. ..

    Article Title: Novel High-Throughput Deoxyribonuclease 1 Assay
    Article Snippet: .. The percentage of DNase I activity was calculated using Equation 1: DNase\u00a0I\u00a0activity (%) =\u00a0 (mean\u00a0velocity\u00a0of\u00a0a\u00a0compound/mean\u00a0velocity\u00a0of\u00a0DMSO)\u00a0\u00d7\u00a0100 (1) In similar assays, recombinant murine EndoG (produced in-house) was used at a concentration of 0.14 μM in 0.1 mM MgCl2 , 10 mM Tris-HCl, pH 7.4; and DNase II (Worthington, Lakewood, NJ) (3.32 nM) was tested in 100 mM sodium citrate buffer, pH 5.0. .. For evaluation of the quality of the assay, Z’ values were calculated using Equation 2: Z\u2019 =\u00a01\u00a0\u2212\u00a0(3SDC +\u00a03SDB )/(MC \u00a0\u2212\u00a0MB ) (2) where M = mean value; SD = standard deviation; C = control; and B = background.

    Incubation:

    Article Title: Epigenetic Control of Cell Cycle-Dependent Histone Gene Expression Is a Principal Component of the Abbreviated Pluripotent Cell Cycle
    Article Snippet: .. Nuclei were then resuspended in RSB buffer supplemented with 1 mM CaCl2 and incubated with increasing concentrations of DNase I (DPRF; Worthington Biochemical Corporation, Lakewood, NJ) for 10 min at room temperature with gentle agitation. ..

    Article Title: Interactions of NBU1 IntN1 and Orf2x Proteins with Attachment Site DNA
    Article Snippet: .. DNase I (Worthington) diluted in DNase I dilution buffer (2.5 mM MgCl2 , 0.5 mM CaCl2 , 10 mM Tris-HCl, pH 7.6, 0.1 mg/ml BSA) to a final concentration of 0.0625 μg/ml was incubated with reaction mixtures for 1 min. ..

    other:

    Article Title: Interactions of NBU1 IntN1 and Orf2x Proteins with Attachment Site DNA
    Article Snippet: The region is dA+dT rich, and protection seen from positions +126 to +129 is subtle because DNase I does not cleave DNA efficiently in this region.

    Article Title: Identification of Viral Peptide Fragments for Vaccine Development
    Article Snippet: In the random digestion step, the use of DNase I in the presence of MnCl2 is critical as this protocol will generate DNA fragments of relatively uniform sizes, which facilitates the reassembly step ( 17 , also see Note ).

    Activity Assay:

    Article Title: Novel High-Throughput Deoxyribonuclease 1 Assay
    Article Snippet: .. The percentage of DNase I activity was calculated using Equation 1: DNase\u00a0I\u00a0activity (%) =\u00a0 (mean\u00a0velocity\u00a0of\u00a0a\u00a0compound/mean\u00a0velocity\u00a0of\u00a0DMSO)\u00a0\u00d7\u00a0100 (1) In similar assays, recombinant murine EndoG (produced in-house) was used at a concentration of 0.14 μM in 0.1 mM MgCl2 , 10 mM Tris-HCl, pH 7.4; and DNase II (Worthington, Lakewood, NJ) (3.32 nM) was tested in 100 mM sodium citrate buffer, pH 5.0. .. For evaluation of the quality of the assay, Z’ values were calculated using Equation 2: Z\u2019 =\u00a01\u00a0\u2212\u00a0(3SDC +\u00a03SDB )/(MC \u00a0\u2212\u00a0MB ) (2) where M = mean value; SD = standard deviation; C = control; and B = background.

    Expressing:

    Article Title: Epigenetic Control of Cell Cycle-Dependent Histone Gene Expression Is a Principal Component of the Abbreviated Pluripotent Cell Cycle
    Article Snippet: .. Analysis of nuclease sensitivity ( ) of the genomic histone HIST2H4 locus to DNase I reveals changes in chromatin structure that accompany increased histone gene expression in hES cells. ..

    Recombinant:

    Article Title: Novel High-Throughput Deoxyribonuclease 1 Assay
    Article Snippet: .. The percentage of DNase I activity was calculated using Equation 1: DNase\u00a0I\u00a0activity (%) =\u00a0 (mean\u00a0velocity\u00a0of\u00a0a\u00a0compound/mean\u00a0velocity\u00a0of\u00a0DMSO)\u00a0\u00d7\u00a0100 (1) In similar assays, recombinant murine EndoG (produced in-house) was used at a concentration of 0.14 μM in 0.1 mM MgCl2 , 10 mM Tris-HCl, pH 7.4; and DNase II (Worthington, Lakewood, NJ) (3.32 nM) was tested in 100 mM sodium citrate buffer, pH 5.0. .. For evaluation of the quality of the assay, Z’ values were calculated using Equation 2: Z\u2019 =\u00a01\u00a0\u2212\u00a0(3SDC +\u00a03SDB )/(MC \u00a0\u2212\u00a0MB ) (2) where M = mean value; SD = standard deviation; C = control; and B = background.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • dnase i  (Worthington Biochemical)
    99
    Worthington Biochemical dnase i
    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant
    Dnase I, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 99/100, based on 431 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dnase i/product/Worthington Biochemical
    Average 99 stars, based on 431 article reviews
    Price from $9.99 to $1999.99
    dnase i - by Bioz Stars, 2020-10
    99/100 stars
    		  Buy from Supplier
    lentiviral vlp stock  (Worthington Biochemical)
    85
    Worthington Biochemical lentiviral vlp stock
    Nullbasic does not inhibit the production of <t>lentiviral</t> VLPs. (a) Schematic diagrams of the three <t>VLP</t> expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins
    Lentiviral Vlp Stock, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lentiviral vlp stock/product/Worthington Biochemical
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    lentiviral vlp stock - by Bioz Stars, 2020-10
    85/100 stars
    		  Buy from Supplier
    cap24  (Worthington Biochemical)
    88
    Worthington Biochemical cap24
    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various <t>CAp24</t> inoculation amounts, as indicated. Transduced
    Cap24, supplied by Worthington Biochemical, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cap24/product/Worthington Biochemical
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cap24 - by Bioz Stars, 2020-10
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Purification, Activity Assay

    Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic does not inhibit the production of lentiviral VLPs. (a) Schematic diagrams of the three VLP expression plasmids and an overview of the methods used to generate lentiviral VLPs. pCMVΔR8.91 plasmid expresses structural and regulatory proteins

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Plasmid Preparation

    Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic inhibits reverse transcription of lentiviral VLPs. (a) Using partially purified VLPs, ERT assays were performed with equivalent amounts of RT activity determined in a homopolymeric primer:template RT assay. Briefly, DNase I-treated VLP supernatant

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Purification, Activity Assay

    Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: Nullbasic diminishes the infectivity of lentiviral VLPs. Nullbasic-EGFP (NB-EGFP) or control EGFP VLPs, produced as per , were transduced into (a) Jurkat, (b) HEK293T, or (c) HeLa cells at various CAp24 inoculation amounts, as indicated. Transduced

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Infection, Produced

    HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: HIV replication is inhibited in activated human CD4 + primary cells expressing NB-ZsGreen1. (a) The two CD4 + populations described in were infected with HIV-1 89.6 containing 20 ng of CAp24 and grown for 21 days. Cell-free supernatant was

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Infection

    HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Journal: Human Gene Therapy

    Article Title: A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

    doi: 10.1089/hum.2012.176

    Figure Lengend Snippet: HIV replication is significantly delayed in Jurkat cell populations expressing Nullbasic-EGFP. The two Jurkat cell lines shown in were infected with HIV-1 pNL4-3 containing 20 ng of CAp24 and grown for 4 weeks. (a) The cell cultures were

    Article Snippet: Lentiviral VLP stock containing 1 μg of CAp24 was treated with DNase I (Worthington Biochemicals, Lakewood, NUJ) and pelleted through 1×phosphate-buffered saline (PBS) containing 20% (v/v) sucrose at 100,000× g for 2 hr, using an SW 41 Ti rotor (Beckman Coulter, Brea, CA).

    Techniques: Expressing, Infection